Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced the appointment of Sandra Milligan , M.D., J.D., President of Aspira Women's Health, to its Board of Directors. "With a distinguished career spanning leadership roles at large and small biopharmaceutical companies, Dr. Milligan brings deep expertise in clinical development and regulatory affairs, including within IBD, that will be invaluable as we execute on our strategy to deliver novel therapies that improve both efficacy and convenience compared to today's standard of care," said Cameron Turtle , DPhil, Chief Executive Officer of Spyre. "We are excited to incorporate her guidance as we progress our novel antibody therapies targeting a4ß7 and TL1A into clinical studies in the upcoming months." Prior to her current role at Aspira, Dr. Milligan served as the Head of Research and Developme
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics to Participate in Upcoming November Investor ConferencesPR Newswire
- Demand For Innovative Therapies for Chronic Illnesses is set to Drive Growth in the Biologics Market is projected to reach USD 817.48 Billion by 2032, growing at a CAGR of 8.5% | FMI [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Guggenheim from $50.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and CombinationsPR Newswire
- Spyre Therapeutics Announces Grants of Inducement AwardsPR Newswire
SYRE
Earnings
- 8/7/24 - Beat
SYRE
Sec Filings
- 10/28/24 - Form 4
- 10/25/24 - Form 144
- 10/23/24 - Form SC
- SYRE's page on the SEC website